Propeller Health research showcased at ERS International Congress 2021

The European Respiratory Society (ERS) International Congress, which took place virtually between September 5-8, 2021, is an annual event that brings together the world’s respiratory experts to present and discuss the latest scientific and clinical advances in the field of respiratory medicine. 

This year, the ERS accepted four abstracts authored by Propeller and its research partners ResMed and Novartis. Read brief summaries of each abstract below.

An Estimate of the European Prevalence of Chronic Obstructive Pulmonary Disease in 2050

Presented with our parent company, ResMed

Summary: Prevalence of chronic obstructive pulmonary disease (COPD) in Europe is expected to rise due to increasing risk factors like smoking and air pollution. Using a time-in-state model, data from the World Bank population projections and Global Burden of Disease data for COPD, researchers projected an estimated 35.2% increase in the number of people and a 39.6% increase in COPD prevalence in Europe by 2050. Efforts to address this burden will require coordinated efforts with advocacy, prevention, diagnosis and treatment.

Assessment of patient engagement and adherence with once-daily indacaterol/glycopyrronium/mometasone (IND/GLY/MF) Breezhaler® digital companion in asthma: interim analysis from Germany

Presented with ResMed and our partner, Novartis 

Summary: Inadequate adherence to inhaled asthma therapy is associated with poor clinical outcomes. Digital companion paired inhaler devices may improve treatment adherence. Patients using the Breezhaler® digital companion showed high medication adherence (74%) and good app engagement. Long-term data from this program may help patients and clinicians better understand factors associated with improved medication adherence.

Initial observed improvement in medication adherence maintained during the COVID-19 pandemic in asthma and COPD

Presented with ResMed

Summary: Controller medication adherence among patients residing in the U.S. with asthma and COPD increased at the start of the COVID-19 pandemic. Researchers sought to determine whether early trends in medication adherence persisted throughout 2020. Among 20,908 participants, researchers observed a steady increase in adherence and an increase in the proportion of patients achieving >75% adherence to their regimen throughout 2020.

Pre-post evaluation of healthcare resource utilization (HCRU) among patients with COPD enrolled in a digital health intervention

Presented by Propeller

Summary: Researchers evaluated the effect of a 6-month digital health intervention on HCRU and medication use in patients with COPD. Patients with COPD were enrolled by their clinical pharmacist in a Propeller program, which included sensors to record inhaler medication use and maintenance medications reminders. Over six months, data showed reductions in HCRU and stable use of maintenance medications in this digital self-management intervention.

For any questions about Propeller’s peer-reviewed clinical research, email help@propellerhealth.com.